Yes, a borderline familial Alzheimer's genetic panel result can still change dementia care decisions, but the lever is the post-test counseling that follows it, not the raw lab readout. Genetic counselors interpret what an ambiguous result does and does not mean, communicate the residual risk, and walk through the practical implications for the patient and family, which is what actually moves a care plan forward even when the gene result itself stays inconclusive, according to counseling practice at the University of Washington Memory and Brain Wellness Center.
A borderline result most often means a variant of uncertain significance, or VUS — a change in a gene like APP, PSEN1, or PSEN2 that cannot yet be classified as clearly disease-causing or clearly harmless. That outcome is not rare: a 2021 review of 452 variants across those three genes found just over 5% landed in this uncertain category under current classification standards, according to Xiao et al. in Frontiers in Aging Neuroscience.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Counts as a Borderline Result on a Familial Alzheimer's Panel?
- How Does a Genetic Counselor Turn an Uncertain Result Into a Decision?
- Does a Borderline Result Affect Eligibility for Newer Alzheimer's Drugs?
- How Strong Is the Risk Signal Behind a Borderline or Uncertain Finding?
- What a Family Can Do With a Borderline Result Right Now
What Counts as a Borderline Result on a Familial Alzheimer's Panel?
A familial Alzheimer's panel looks for mutations in APP, PSEN1, and PSEN2, the three genes tied to autosomal-dominant early-onset Alzheimer's — a pattern where a single inherited copy of a disease-causing variant is enough to cause the condition, typically before age 65. Clinical genetic testing is recommended only for families showing this inheritance pattern, per the joint 2011 guideline from the National Society of Genetic Counselors and American College of Medical Genetics and Genomics, which also advises against routine APOE testing in general clinical practice. A borderline or uncertain result means the lab found a variant but cannot yet say whether it causes disease. This differs from a clear positive (a known pathogenic mutation) or a clear negative (no concerning variant found).
A negative result does not rule out a genetic cause, because panels have limited detection, so families can still carry an undiscovered genetic risk even after testing comes back clean, according to the same UW Memory and Brain Wellness Center guidance. Uncertainty here is not necessarily permanent. A 2020 functional study tested 90 previously uncertain APP, PSEN1, and PSEN2 variants in a cell-based laboratory assay and reclassified 19 of them as likely pathogenic, while identifying five as possibly protective, according to Hsu et al. in Neurobiology of Disease. A VUS today can become a resolved answer later as the evidence base grows.
How Does a Genetic Counselor Turn an Uncertain Result Into a Decision?
The counseling session, not the lab report, is where a borderline result gets translated into something a family can act on. A genetic counselor explains the practical meaning of the uncertainty, estimates what risk level is still reasonable to assume, and addresses what the finding implies for siblings, children, and other relatives, per the UW Memory and Brain Wellness Center. This matters because families rarely choose testing for purely technical reasons.
A 2025 study of 138 dementia patients eligible for genetic testing in Amsterdam found that 54% chose to undergo it, and those who did were more often people with better cognition, higher quality of life, and a diagnosis that was still undetermined. Their decisions were driven more by personal values — informing relatives, reducing uncertainty — than by how strong or weak the genetic result turned out to be, according to the Alzheimer Europe summary of that study. In practice, this means a borderline panel result can still prompt concrete next steps: closer monitoring for a patient with early cognitive symptoms, a conversation about family planning or relative testing, or a referral for deeper functional variant analysis if the family wants to pursue it further.
Does a Borderline Result Affect Eligibility for Newer Alzheimer's Drugs?
A separate genetic consideration has become more consequential for care decisions since anti-amyloid drugs reached the market. The FDA-approved labels for donanemab and lecanemab recommend APOE genotyping before starting treatment, because having two copies of the APOE ε4 allele substantially raises the risk of ARIA, or amyloid-related imaging abnormalities — swelling or bleeding visible on brain scans. The FDA stopped short of making the test mandatory, leaving that call to clinical judgment, according to GenomeWeb and 360Dx coverage of the drug labels. This is a different gene and a different purpose than a familial Alzheimer's panel: APOE testing informs drug safety screening, while APP/PSEN1/PSEN2 testing addresses inherited disease risk.
A family that has already undergone a familial panel may still face a separate APOE conversation before starting an anti-amyloid drug. The real-world weight of an APOE result on that treatment decision is modest. A simulation study using anti-amyloid trial data found that withholding treatment from every APOE ε4/ε4 homozygote would require testing 15 to 30 patients to prevent a single ARIA event, and would cut total ARIA events by only 10% to 30%. That makes APOE genotype a weak standalone screening tool, better suited to shared decision-making between patient and clinician than to an automatic yes-or-no cutoff, per the PMC simulation study.
How Strong Is the Risk Signal Behind a Borderline or Uncertain Finding?
Even outside the VUS category, genetic risk markers for Alzheimer's vary widely in strength, and that context helps families weigh a borderline result. Australia's Royal Australian College of General Practitioners states that APOE testing has limited clinical utility for diagnosing Alzheimer's and is not recommended in general practice. Heterozygous ε4 carriers face roughly triple the risk of Alzheimer's, while ε4/ε4 homozygotes face roughly 15 times the risk — but the RACGP stresses that ε4 is neither necessary nor sufficient to cause the disease, according to RACGP's Genomics in General Practice guidance. A familial-gene VUS sits in a different category still: it is not a risk-multiplier like APOE, but an unresolved question about whether the variant causes disease at all.
Treating a VUS as equivalent to a confirmed pathogenic mutation, or dismissing it as equivalent to a clean negative, both overstate what the result actually shows. Guidance on how to handle this uncertainty is due for an update. The NSGC Dementia Workgroup has received formal approval to revise the 2011 practice guideline, reflecting that it predates both the anti-amyloid drug approvals and newer methods for classifying variants, according to a 2025 summary tracked in PMC. Families with a borderline result today are being counseled under a framework that the field's own specialists consider overdue for revision.
What a Family Can Do With a Borderline Result Right Now
A borderline panel result is not a dead end, and there are concrete steps a family can take with a genetic counselor rather than waiting for a definitive answer:.
- Ask whether the specific variant has been re-evaluated recently — reclassification happens as labs gather more functional and population data.
- Clarify whether the finding changes eligibility conversations for anti-amyloid treatment, which turns on APOE status, not on the familial panel result.
- Discuss what the result means for siblings, children, or other blood relatives, since inheritance risk is a family matter, not just an individual one.
- Revisit the result periodically with the testing lab or counselor, since a VUS today can be reclassified as new evidence accumulates, as happened for 19 of 90 variants in the 2020 Neurobiology of Disease study.
- Keep the genetic finding separate from the APOE question if anti-amyloid treatment becomes relevant later, since the two tests answer different clinical questions.
